Uses
MC180295 can be useful in combination therapy of BET proteolysis targeting chimeric mol. with CDK9 inhibitor against human multiple myeloma cells.
Biological Activity
MC180295 ((rel)-MC180295) is a novel potent and selective CDK9 inhibitor with IC50 of 5 nM, at least 22-fold selective for CDK9 over other CDKs.
in vivo
MC180295 has antitumor and immunoallergic activity.
target
| Target | Value |
CDK9-Cyclin T1
(Cell-free assay) | 5 nM |
CDK4-Cyclin D
(Cell-free assay) | 112 nM |
CDK1-Cyclin B
(Cell-free assay) | 138 nM |
| CDK5-P35 < br/> (Cell-free assay) | 159 nM |
CDK5-P25
(Cell-free assay) | 186 nM |
